⬇ ⬇ ⬆ ⬇Therapeutic Classification: vascular headache suppressants
Pharmacologic Classification: five ht1 agonists
⬆ ⬇ ⬆ ⬇ ⬆ ⬇Absorption: Well absorbed (97%) after SUBQ administration. Absorption after oral administration is incomplete and significant amounts undergo substantial hepatic metabolism, resulting in poor bioavailability (14%). Well absorbed after intranasal administration.
Distribution: Well distributed to tissues.
Half-Life: 2 hr.
⬆ ⬇(relief of migraine)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | within 30 min | 2–4 hr | up to 24 hr |
| SUBQ | 30 min | up to 2 hr | up to 24 hr |
| Nasal | within 60 min | 2 hr | unknown |
⬆ ⬇Contraindicated in:
Use Cautiously in:
Exercise Extreme Caution in:
⬆ ⬇CV: angina, chest pressure, chest tightness, coronary vasospasm, ECG changes, MI, transient hypertension
Derm: tingling, warm sensation, burning sensation, cool sensation, flushing
EENT: alterations in vision, nasal sinus discomfort, throat discomfort
GI: abdominal discomfort, dysphagia
Local: injection site reaction
MS: jaw discomfort, muscle cramps, myalgia, neck pain, neck stiffness
Neuro: dizziness, vertigo, anxiety, drowsiness, fatigue, feeling of heaviness, feeling of tightness, headache, malaise, numbness, tight feeling in head, weakness
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)
⬆ ⬇Drug-drug:
Drug-Natural Products:
⬆ ⬇Hepatic Impairment
⬆ ⬇ ⬆ ⬇ ⬆ ⬇ ⬆ ⬇ ⬆ ⬇ ⬆ ⬇ ⬆ ⬇ ⬆NDC Code
